Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: drug prices

Advocacy Team Celebrates Healthcare Fixes, Prepares to Face New Threats

Angus Worthing, MD, FACP, FACR  |  March 1, 2018

Greetings, Advocates! Great news for the rheumatology community came on Feb. 9, when the Bipartisan Budget Act of 2018 was enacted. It contains several critical healthcare fixes pertinent to rheumatology. First, after hundreds of emails, meetings, letters to the editor, an op-ed, and a forceful 109-member coalition (led by the ACR and including many state…

Filed under:Legislation & Advocacy Tagged with:ACR advocacyACR Government Affairs CommitteeAngus WorthingBipartisan Budget ActD.C. updateGAChealthcare fixeshigh drug costsPart B drug costs

U.S. Healthcare Spending to Climb 5.3 Percent in 2018

Yasmeen Abutaleb  |  February 14, 2018

WASHINGTON (Reuters)—United States health spending is projected to rise 5.3% in 2018, reflecting rising prices of medical goods and services and higher Medicaid costs, a U.S. government health agency said on Wednesday, an upward trend it forecasts for the next decade. The increase represents a sharp uptick from 2017 spending, which the U.S. Centers for…

Filed under:Professional Topics Tagged with:higher Medicaid costsU.S. Centers for Medicare and Medicaid Services (CMS)U.S. healthcare spending 2018

U.S. Senate Votes to Confirm Azar as Health Secretary

Reuters Staff  |  January 24, 2018

WASHINGTON (Reuters)—The U.S. Senate on Wednesday voted to confirm former pharmaceutical industry executive and lobbyist Alex Azar as the next Health and Human Services secretary. Azar will oversee the Trump administration’s response to the opioid epidemic, its efforts to weaken the Affordable Care Act, commonly called Obamacare, and address rising prescription drug prices. The Senate…

Filed under:Uncategorized Tagged with:Alex AzarHealth and Human Services secretary

Rheumatologists Air Frustrations with Pharmacy Benefit Managers at Annual Meeting

Larry Beresford  |  January 19, 2018

SAN DIEGO—Pharmacy benefit managers (PBMs) and their impact on drug prices and access to high-cost medications by the patients rheumatologists treat was a major theme at the 2017 ACR/ARHP Annual Meeting Nov. 3–8. In one session, industry experts tried to clarify the role for prior authorizations and drug formulary policies and explored ways to constructively…

Filed under:Drug UpdatesLegislation & AdvocacyMeeting ReportsProfessional Topics Tagged with:ACR/ARHP Annual MeetingAdvocacydrugpharmacy benefit managers (PBMs)

Should Patients with Rheumatic Disease Switch from Biologic to Biosimilar?

Susan Bernstein  |  January 19, 2018

SAN DIEGO—Should patients with rheumatic diseases switch from a biologic to its biosimilar? At the 2017 ACR/ARHP Annual Meeting’s Great Debate, held Nov. 5, two rheumatologists argued whether to switch or stay put based on safety, efficacy and potential cost savings. First to the podium to make the case for switching, Jonathan Kay, MD, tweaked…

Filed under:Biologics/DMARDsDrug UpdatesInsuranceMeeting Reports Tagged with:ACR/ARHP Annual MeetingBiologicsBiosimilarsdrug costinsurance

The American College of Rheumatology’s Legislative Successes of 2017

Larry Beresford  |  January 19, 2018

SAN DIEGO—The 2017 ACR/ARHP Annual Meeting, Nov. 3–8, presented opportunities to highlight its 2017 legislative advocacy victories, some of which were resolved just weeks before the conference began, as well as issues that are still outstanding. In the session, Legislative & Regulatory Update 2017, Angus Worthing, MD, chair of the ACR’s Government Advocacy Committee and…

Filed under:Legislation & AdvocacyMeeting ReportsProfessional Topics Tagged with:ACR/ARHP Annual MeetingAdvocacyLegislation

ACR Advocacy: Past Wins, Future Outlook

Angus Worthing, MD, FACP, FACR  |  January 18, 2018

Greetings, advocates! Your government is back to work after ending a brief government shutdown by passing a short-term continuing resolution (CR), which will keep the government running at current funding levels into February. At some point, it would be great for Congress to pass a budget (instead of a CR) and to enact bipartisan plans…

Filed under:Legislation & AdvocacyPractice SupportProfessional Topics Tagged with:2017 ACR/ARHP Annual MeetingAngus Worthingdrug costsWashington D.C. update

Health Secretary Nominee Indicates Support for Medicaid Overhaul

Yasmeen Abutaleb  |  January 9, 2018

WASHINGTON (Reuters)—Alex Azar, a former drug industry executive and lobbyist nominated to run the U.S. Department of Health and Human Services, indicated on Tuesday he supported a Republican bid to overhaul Medicaid and again vowed to tackle high drug prices. Azar appeared before the Senate Finance Committee on Tuesday, which will ultimately decide whether to…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Alex AzarDepartment of Health and Human ServicesTrump administrationU.S. Department of Health and Human Services

The ACR’s 2018 Legislative & Regulatory Priorities

Kelly Tyrrell  |  January 5, 2018

A recent Politico article outlined the looming agenda facing Congress as 2018 begins: Fund the government, raise the debt ceiling, modify spending caps, address healthcare subsidies, allocate additional funds for disaster relief, and address the status of millions of undocumented young immigrants.1 Amid all that activity, the ACR, through its Government Affairs Committee (GAC) and…

Filed under:Legislation & Advocacy Tagged with:ACR advocacyalternative payment models (APMs)MIPSPart B drug costspharmacy benefit managers (PBMs)

United Therapeutics to Pay $210 Million to Resolve U.S. Kickback Probe

Nate Raymond  |  December 20, 2017

BOSTON (Reuters)—United Therapeutics Corp will pay $210 million to resolve U.S. claims that the drugmaker used a charity as a conduit to illegally cover Medicare patients’ out-of-pocket drug costs in order to eliminate price sensitivity and to boost sales. The U.S. Attorney’s Office in Massachusetts on Wednesday announced the settlement, one of the first to…

Filed under:Legal UpdatesProfessional Topics Tagged with:charity conduit lawsuitMedicare patientssubsidizing co-paymentsUnited Therapeutics Corp

  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 25
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences